Paper32235331
Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.
Montemagno C and 1 other. Cancers (Basel), 2020. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine. Papers, record 32235331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32235331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Metastatic Heterogeneity of Breast Cancer: Companion and Theranostic Approach in Nuclear Medicine.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References100
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21455667 | Hematogenous and lymphatic tumor cell dissemination may be detected in patients diagnosed with ductal carcinoma in situ of the breast. | Breast Cancer Res Treat | 2012 | https://conductscience.org/library/papers/21455667 | PubMed |
| 2 | 23237552 | On the origin of cancer metastasis. | Crit Rev Oncog | 2013 | https://conductscience.org/library/papers/23237552 | PubMed |
| 3 | 21207426 | Disseminated tumor cells in the bone marrow of patients with ductal carcinoma in situ. | Int J Cancer | 2011 | https://conductscience.org/library/papers/21207426 | PubMed |
| 4 | 29752180 | [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. | Lancet Oncol | 2018 | https://conductscience.org/library/papers/29752180 | PubMed |
| 5 | 16826579 | Primary breast cancer phenotypes associated with propensity for central nervous system metastases. | Cancer | 2006 | https://conductscience.org/library/papers/16826579 | PubMed |
| 6 | 17957189 | Models, mechanisms and clinical evidence for cancer dormancy. | Nat Rev Cancer | 2007 | https://conductscience.org/library/papers/17957189 | PubMed |
| 7 | 27151988 | Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using 89Zr-Trastuzumab PET/CT. | J Nucl Med | 2016 | https://conductscience.org/library/papers/27151988 | PubMed |
| 8 | 15992701 | New insights on cell death from radiation exposure. | Lancet Oncol | 2005 | https://conductscience.org/library/papers/15992701 | PubMed |
| 9 | 18026089 | Adaptive immunity maintains occult cancer in an equilibrium state. | Nature | 2007 | https://conductscience.org/library/papers/18026089 | PubMed |
| 10 | 29042793 | Theranostics in nuclear medicine practice. | Onco Targets Ther | 2017 | https://conductscience.org/library/papers/29042793 | PubMed |
| 11 | 26536664 | Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with ⁸⁹Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. | Oncotarget | 2015 | https://conductscience.org/library/papers/26536664 | PubMed |
| 12 | 27609789 | 68Ga/177Lu-NeoBOMB1, a Novel Radiolabeled GRPR Antagonist for Theranostic Use in Oncology. | J Nucl Med | 2017 | https://conductscience.org/library/papers/27609789 | PubMed |
| 13 | 22711854 | Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. | J Clin Oncol | 2012 | https://conductscience.org/library/papers/22711854 | PubMed |
| 14 | 26392755 | Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials. | Drug Des Devel Ther | 2015 | https://conductscience.org/library/papers/26392755 | PubMed |
| 15 | 28618966 | 68Ga/177Lu-labeled DOTA-TATE shows similar imaging and biodistribution in neuroendocrine tumor model. | Tumour Biol | 2017 | https://conductscience.org/library/papers/28618966 | PubMed |
| 16 | 17973263 | HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. | Int J Cancer | 2008 | https://conductscience.org/library/papers/17973263 | PubMed |
| 17 | 10684910 | Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. | N Engl J Med | 2000 | https://conductscience.org/library/papers/10684910 | PubMed |
| 18 | 23487015 | Synthesis, preclinical validation, dosimetry, and toxicity of 68Ga-NOTA-anti-HER2 Nanobodies for iPET imaging of HER2 receptor expression in cancer. | J Nucl Med | 2013 | https://conductscience.org/library/papers/23487015 | PubMed |
| 19 | 28613198 | Lu-177-PSMA-617 Prostate-Specific Membrane Antigen Inhibitor Therapy in Patients with Castration-Resistant Prostate Cancer: Stability, Bio-distribution and Dosimetry. | Mol Imaging Radionucl Ther | 2017 | https://conductscience.org/library/papers/28613198 | PubMed |
| 20 | 12829800 | Repeated observation of breast tumor subtypes in independent gene expression data sets. | Proc Natl Acad Sci U S A | 2003 | https://conductscience.org/library/papers/12829800 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41021173 | Deciphering key chemotherapeutic drug targets within tyrosine metabolism for breast cancer and advancing a wide-ranging diagnostic strategy. | Discov Oncol | 2025 | https://conductscience.org/library/papers/41021173 | PubMed |
| 37605516 | Histologic heterogeneity predicts patient prognosis of HER2-positive metastatic breast cancer: A retrospective study based on SEER database. | Cancer Med | 2023 | https://conductscience.org/library/papers/37605516 | PubMed |
| 35953532 | Pivotal models and biomarkers related to the prognosis of breast cancer based on the immune cell interaction network. | Sci Rep | 2022 | https://conductscience.org/library/papers/35953532 | PubMed |
| 35451558 | miR-450a exerts oncosuppressive effects in breast carcinoma by targeting CREB1. | Kaohsiung J Med Sci | 2022 | https://conductscience.org/library/papers/35451558 | PubMed |
| 34684834 | Palmatine, a Bioactive Protoberberine Alkaloid Isolated from Berberis cretica, Inhibits the Growth of Human Estrogen Receptor-Positive Breast Cancer Cells and Acts Synergistically and Additively with Doxorubicin. | Molecules | 2021 | https://conductscience.org/library/papers/34684834 | PubMed |
| 33925632 | Theranostic Advances in Breast Cancer in Nuclear Medicine. | Int J Mol Sci | 2021 | https://conductscience.org/library/papers/33925632 | PubMed |
Genes15
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32235331
GET https://conductscience.org/api/papers/v1/32235331/references?page=2